Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Hepatitis

  Free Subscription


Articles published in J Med Virol

Retrieve available abstracts of 100 articles:
HTML format



Single Articles


    August 2022
  1. SARFARAZ N, Somarowthu S, Bouchard MJ
    The Interplay of Long Non-Coding RNAs and Hepatitis B Virus.
    J Med Virol. 2022 Aug 9. doi: 10.1002/jmv.28058.
    PubMed     Abstract available


    July 2022
  2. CHEEMA HA, Shahid A, Aziz H
    Severe acute pediatric hepatitis: the undue emphasis on adenovirus needs to be reassessed.
    J Med Virol. 2022 Jul 20. doi: 10.1002/jmv.28014.
    PubMed     Abstract available


  3. LIAN J, Kuang W, Jia H, Lu Y, et al
    Pegylated interferon-alpha-2b combined with tenofovir disoproxil fumarate, granulocyte-macrophage colony-stimulating factor, and hepatitis B vaccine treatment for naive HBeAg-positive chronic hepatitis B patients: A prospective, multicenter, randomize
    J Med Virol. 2022 Jul 14. doi: 10.1002/jmv.28003.
    PubMed     Abstract available


  4. ZHANG Q, Liang J, Yin J, Jiang Y, et al
    Real-life impact of tenofovir disoproxil fumarate and entecavir therapy on lipid profile, glucose and uric acid in chronic hepatitis B patients.
    J Med Virol. 2022 Jul 6. doi: 10.1002/jmv.27977.
    PubMed     Abstract available


  5. RATHO RK, Thakur V, Arya S, Singh MP, et al
    Placenta as a site of HEV replication and inflammatory cytokines modulating the immunopathogenesis of HEV in pregnant women.
    J Med Virol. 2022;94:3457-3463.
    PubMed     Abstract available


    June 2022
  6. ZHONG S, Liu Z, Zhou Y, Zhang T, et al
    Longitudinal mapping of hepatitis B vaccine-induced B-cell linear epitopes in healthy individuals.
    J Med Virol. 2022 Jun 8. doi: 10.1002/jmv.27926.
    PubMed     Abstract available


  7. ZHENG XQ, Li X, Liu J, Shi L, et al
    Horizontal transmission might be a common route of hepatitis B virus exposure in highly endemic areas.
    J Med Virol. 2022 Jun 2. doi: 10.1002/jmv.27905.
    PubMed     Abstract available


  8. OHTA A, Ogawa E, Murata M, Matsumoto Y, et al
    Impact of the PNPLA3 genotype on the risk of hepatocellular carcinoma after hepatitis C virus eradication.
    J Med Virol. 2022 Jun 2. doi: 10.1002/jmv.27904.
    PubMed     Abstract available


    May 2022
  9. QI X, Li F, Zhang Y, Zhu H, et al
    STAT4 genetic polymorphism significantly affected HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients receiving Peginterferon-alpha therapy: A prospective cohort study in China Running title: STAT4 variation affecting response to PegIF
    J Med Virol. 2022 May 24. doi: 10.1002/jmv.27880.
    PubMed     Abstract available


  10. ZENG QL, Yu ZJ, Lv J, Zhang HX, et al
    Sofosbuvir-based Therapy for Late Pregnant Women and Infant with Severe Chronic Hepatitis C: A Case Series Study.
    J Med Virol. 2022 May 20. doi: 10.1002/jmv.27877.
    PubMed     Abstract available


  11. LIANG LY, Yip TC, Lai JC, Lam AS, et al
    Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate.
    J Med Virol. 2022 May 17. doi: 10.1002/jmv.27863.
    PubMed     Abstract available


  12. HAKIM MS
    The recent outbreak of acute and severe hepatitis of unknown etiology in children: a possible role of human adenovirus infection?
    J Med Virol. 2022 May 16. doi: 10.1002/jmv.27856.
    PubMed     Abstract available


  13. XIE Z, Deng K, Xia Y, Zhang C, et al
    Efficacy and safety of direct-acting antiviral therapies and baseline predictors for treatment outcomes in hepatitis C patients: a multi-center, real-world study in Guangdong, China.
    J Med Virol. 2022 May 11. doi: 10.1002/jmv.27851.
    PubMed     Abstract available


  14. MALONGA GA, Dienta S, Traore FT, Maiga Z, et al
    Human Herpesvirus 8 seroprevalence among blood donors in Mali.
    J Med Virol. 2022 May 11. doi: 10.1002/jmv.27850.
    PubMed     Abstract available


  15. KOC OM, van Oorschot E, Brandts L, Lashof AO, et al
    Timing of primary three dose hepatitis B vaccination and postvaccination serologic testing among a large cohort of healthy adults.
    J Med Virol. 2022 May 10. doi: 10.1002/jmv.27848.
    PubMed     Abstract available


    April 2022
  16. KHAN YH, Mallhi TH, Alanazi AS, Butt MH, et al
    Outbreak of Acute Hepatitis of Unknown etiology in Children; The Critical Role of Healthcare Professionals in Neutralizing Misleading Narratives during the COVID-19 Pandemic.
    J Med Virol. 2022 Apr 29. doi: 10.1002/jmv.27819.
    PubMed    


  17. ZHANG C, Liu Y, Li J, Liu H, et al
    Dose-response relationship between qAnti-HBc and liver inflammation in chronic hepatitis B with normal or mildly elevated ALT based on liver biopsy.
    J Med Virol. 2022 Apr 13. doi: 10.1002/jmv.27779.
    PubMed     Abstract available


  18. ZHAO D, Yu S, Guo P, Zhang X, et al
    Identification of potential plasma markers for hepatitis B virus-related chronic hepatitis and liver fibrosis/cirrhosis.
    J Med Virol. 2022 Apr 5. doi: 10.1002/jmv.27761.
    PubMed     Abstract available


    March 2022
  19. LIN P, Wen DY, Pang JS, Liao W, et al
    Proteomics profiling of nontumor liver tissues identifies prognostic biomarkers in hepatitis B-related hepatocellular carcinoma.
    J Med Virol. 2022 Mar 21. doi: 10.1002/jmv.27732.
    PubMed     Abstract available


  20. YU J, Shi X, Yu H, Wu J, et al
    Impact of hepatitis-B-surface-antigen-positive grafts on liver transplantation in patients with benign and malignant liver disease.
    J Med Virol. 2022 Mar 7. doi: 10.1002/jmv.27703.
    PubMed     Abstract available


    February 2022
  21. WU J, Xu Y, Cui Y, Bortolanza M, et al
    Dynamic changes of serum metabolites associated with infection and severity of patients with acute hepatitis E infection.
    J Med Virol. 2022 Feb 23. doi: 10.1002/jmv.27669.
    PubMed     Abstract available


  22. JACKSON K, Holgate T, Tekoaua R, Nicholson S, et al
    Evaluation of dried blood spots for hepatitis B and D serology and nucleic acid testing.
    J Med Virol. 2022;94:642-648.
    PubMed     Abstract available


    January 2022
  23. MOREIRA LVL, Malheiros AP, Barbosa KMV, Freitas PEB, et al
    The first evidence of Hepatitis A virus subgenotype IIIA in the Eastern Brazilian Amazon, 1982-1983.
    J Med Virol. 2022 Jan 25. doi: 10.1002/jmv.27625.
    PubMed     Abstract available


  24. LUO M, Chen Z, Liu M, Liang Q, et al
    Inhibitory Activities of Ranunculus japonicus Thunb. Ethanol Extract against Hepatitis B Virus.
    J Med Virol. 2022 Jan 24. doi: 10.1002/jmv.27621.
    PubMed     Abstract available


  25. LEON FJF, Silva LLD, Santos AC, Duarte da Costa V, et al
    Immunological and virological aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hepatitis C virus.
    J Med Virol. 2022 Jan 22. doi: 10.1002/jmv.27614.
    PubMed     Abstract available


  26. YU K, Mei Y, Wang Z, Liu B, et al
    LncRNA LINC00924 upregulates NDRG2 to inhibit epithelial-mesenchymal transition via sponging miR-6755-5p in hepatitis B virus-related hepatocellular carcinoma.
    J Med Virol. 2022 Jan 8. doi: 10.1002/jmv.27578.
    PubMed     Abstract available


    December 2021
  27. XIE Y, Ma H, Feng B, Song G, et al
    Combining the HBcrAg decline and HBV mutations predicts spontaneous HBeAg seroconversion in chronic hepatitis B patients during the immune clearance phase.
    J Med Virol. 2021 Dec 24. doi: 10.1002/jmv.27545.
    PubMed     Abstract available


  28. DENG H, Feng Q, Wu Y, Lin H, et al
    Immune response to hepatitis B vaccination in human immunodeficiency virus-positive patients in China: A 2-year retrospective study.
    J Med Virol. 2021 Dec 14. doi: 10.1002/jmv.27523.
    PubMed     Abstract available


    November 2021
  29. BOLINA-SANTOS E, Chaves DG, da Silva-Malta MCF, Carmo RA, et al
    HCV infection in hemophilia A patients is associated with altered cytokines and chemokines profile and might modulate the levels of FVIII inhibitor.
    J Med Virol. 2021 Nov 5. doi: 10.1002/jmv.27432.
    PubMed     Abstract available


  30. ZHENG S, Li M, Pan X, Huang X, et al
    Association of IL-32 rs28372698 polymorphism with active chronic HBV infection.
    J Med Virol. 2021;93:6236-6240.
    PubMed     Abstract available


    October 2021
  31. JI Q, Chu X, Zhou Y, Liu X, et al
    Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients.
    J Med Virol. 2021 Oct 2. doi: 10.1002/jmv.27374.
    PubMed     Abstract available


    September 2021
  32. WU J, Bortolanza M, Zhai G, Shang A, et al
    Gut Microbiota Dysbiosis Associated with Plasma Levels of Interferon-gamma and Viral Load in Patients with Acute Hepatitis E Infection.
    J Med Virol. 2021 Sep 22. doi: 10.1002/jmv.27356.
    PubMed     Abstract available


  33. KAZMI SK, Khan FMA, Natoli V, Hunain R, et al
    Viral hepatitis amidst COVID-19 in Africa: Implications and Recommendations.
    J Med Virol. 2021 Sep 10. doi: 10.1002/jmv.27330.
    PubMed     Abstract available


  34. NICOLINI LA, Menzaghi B, Molteni C, Vichi F, et al
    Comments on "Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C".
    J Med Virol. 2021 Sep 9. doi: 10.1002/jmv.27329.
    PubMed    


  35. YAO K, Wang J, Wang L, Xia J, et al
    Association of anti-HBc and liver inflammation in HBeAg-negative chronic hepatitis B virus infected patients with normal ALT and detectable HBV DNA.
    J Med Virol. 2021 Sep 9. doi: 10.1002/jmv.27327.
    PubMed     Abstract available


    August 2021
  36. TARAFDAR S, Virata ML, Yan H, Zhong L, et al
    Multiple Epitopes of Hepatitis B Virus Surface Antigen Targeted by Human Plasma-derived Immunoglobulins Coincide with Clinically Observed Escape Mutations.
    J Med Virol. 2021 Aug 18. doi: 10.1002/jmv.27278.
    PubMed     Abstract available


  37. YAO Y, Shen Y, Shao H, Liu Y, et al
    Polymorphisms of RIG-I-like receptor influence HBV clearance in Chinese Han population.
    J Med Virol. 2021;93:4957-4965.
    PubMed     Abstract available


    July 2021
  38. WEI MT, Le MH, Landis C, Trinh H, et al
    Evaluation of ethnic influence in the application of a hepatocellular carcinoma predictive model for chronic hepatitis C.
    J Med Virol. 2021 Jul 5. doi: 10.1002/jmv.27168.
    PubMed     Abstract available


    June 2021
  39. LEUMI S, El Kassas M, Zhong J
    Hepatitis C virus-genotype 4: a poorly characterized endemic genotype.
    J Med Virol. 2021 Jun 29. doi: 10.1002/jmv.27165.
    PubMed     Abstract available


  40. TADA T, Kurosaki M, Nakamura S, Hasebe C, et al
    Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
    J Med Virol. 2021 Jun 25. doi: 10.1002/jmv.27157.
    PubMed     Abstract available


  41. JI H, Chen S, He Q, Wang W, et al
    The different replication between nonenveloped and quasi-enveloped hepatitis E virus.
    J Med Virol. 2021 Jun 2. doi: 10.1002/jmv.27121.
    PubMed     Abstract available


  42. WANG Y, Li X, Chen Q, Jiao F, et al
    The relationship between liver pathological inflammation degree and pyroptosis in chronic hepatitis B patients.
    J Med Virol. 2021 Jun 1. doi: 10.1002/jmv.27114.
    PubMed     Abstract available


  43. SAJJAD M, Ali S, Baig S, Sharafat S, et al
    HBV S antigen evolution in the backdrop of HDV infection affects epitope processing and presentation.
    J Med Virol. 2021;93:3714-3729.
    PubMed     Abstract available


  44. JACKSON K, Tekoaua R, Li X, Locarnini S, et al
    Real-world application of the Xpert(R) HBV viral load assay on serum and dried blood spots.
    J Med Virol. 2021;93:3707-3713.
    PubMed     Abstract available


    April 2021
  45. XU Z, Lin JZ, Zeng YF, Yang XH, et al
    Changes of cytokine levels and T cell surface molecules in patients with chronic hepatitis B and the association with functional cure.
    J Med Virol. 2021 Apr 29. doi: 10.1002/jmv.27041.
    PubMed     Abstract available


  46. BULFONI M, Pravisani R, Dalla E, Cesselli D, et al
    miRNA expression profiles in liver grafts of HCV and HIV/HCV infected recipients, six months after liver transplantation.
    J Med Virol. 2021 Apr 5. doi: 10.1002/jmv.26999.
    PubMed     Abstract available


    March 2021
  47. ELHENCE A, Singh A, Anand A, Kumar R, et al
    Real-World Re-Treatment Outcomes of Direct-Acting Antiviral Therapy Failure in Patients with Chronic Hepatitis C.
    J Med Virol. 2021 Mar 30. doi: 10.1002/jmv.26971.
    PubMed     Abstract available


  48. BEN DHIFALLAH I, Ayouni K, Jmel H, Kammoun W, et al
    Strong association of functional polymorphism in IL-12B with susceptibility to Chronic Hepatitis B in Tunisia.
    J Med Virol. 2021 Mar 19. doi: 10.1002/jmv.26946.
    PubMed     Abstract available


  49. FEDORCHENKO SV, Martynovych T, Klimenko Z, Solianyk I, et al
    Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir, dasabuvir + sofosbuvir + ribavirin in patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous with first- and second-generation NS5A inhibitors.
    J Med Virol. 2021 Mar 11. doi: 10.1002/jmv.26935.
    PubMed     Abstract available


  50. HU Q, Wang Q, Zhang Y, Tao S, et al
    Baseline serum exosome-derived miRNAs predict HBeAg seroconversion in chronic hepatitis B patients treated with peginterferon.
    J Med Virol. 2021 Mar 5. doi: 10.1002/jmv.26916.
    PubMed     Abstract available


    December 2020
  51. MIRANDA NTGP, de Souza RL, Monteiro JC, Costa IB, et al
    Seroprevalence of HBV and HCV in female sex workers from four cities in the state of Para, northern Brazil.
    J Med Virol. 2020 Dec 25. doi: 10.1002/jmv.26759.
    PubMed     Abstract available


  52. BAKI AA, Haque W, Giti S, Khan AA, et al
    Hepatitis E virus genotype 1f outbreak in Bangladesh, 2018.
    J Med Virol. 2020 Dec 17. doi: 10.1002/jmv.26739.
    PubMed     Abstract available


  53. SARKAR S, Khanna P, Singh AK
    Impact of COVID-19 in patients with concurrent co-infections: a systematic review and meta-analyses.
    J Med Virol. 2020 Dec 17. doi: 10.1002/jmv.26740.
    PubMed     Abstract available


    November 2020
  54. ALVARADO-ESQUIVEL C, Gutierrez-Martinez VD, Ramirez-Valles EG, Sifuentes-Alvarez A, et al
    Hepatitis E Virus infection and waste pickers: a case-control seroprevalence study.
    J Med Virol. 2020 Nov 24. doi: 10.1002/jmv.26688.
    PubMed     Abstract available


  55. CHUA JV, Ntem-Mensah A, Abutaleb A, Husson J, et al
    Short-duration treatment with the novel non-nucleoside inhibitor CDI-31244 plus sofosbuvir/velpatasvir for chronic hepatitis C: an open-label study.
    J Med Virol. 2020 Nov 5. doi: 10.1002/jmv.26652.
    PubMed     Abstract available


    October 2020
  56. GONG S, Hao X, Bi Y, Yang C, et al
    Hepatitis E viral infection regulates estrogen signaling pathways: inhibition of the cAMPK-PKA -CREB and PI3K-AKT-mTOR signaling pathways.
    J Med Virol. 2020 Oct 31. doi: 10.1002/jmv.26641.
    PubMed     Abstract available


  57. SINGH AK, Rooge SB, Varshney A, Vasudevan M, et al
    Identification of miRNAs associated with dendritic cell dysfunction during Acute and Chronic Hepatitis B virus infection.
    J Med Virol. 2020 Oct 27. doi: 10.1002/jmv.26629.
    PubMed     Abstract available


    September 2020
  58. AYOUNI K, Kharroubi G, Mallekh R, Hammami W, et al
    Seroprevalence of hepatitis A virus infection in Central-West of Tunisia.
    J Med Virol. 2020 Sep 28. doi: 10.1002/jmv.26563.
    PubMed     Abstract available


  59. BARUAH V, Tiwari D, Hazam RK, Bose M, et al
    Prognostic, clinical and therapeutic importance of RANTES-CCR5 axis in hepatitis A infection: A multi-approach study.
    J Med Virol. 2020 Sep 25. doi: 10.1002/jmv.26557.
    PubMed     Abstract available


  60. WANG ML, Liao J, Ye F, Tao YC, et al
    Distribution and factors associated with serum HBV pregenomic RNA levels in Chinese chronic hepatitis B patients.
    J Med Virol. 2020 Sep 19. doi: 10.1002/jmv.26529.
    PubMed     Abstract available


  61. TAMORI A, Kimura K, Kioka K, Enomoto H, et al
    Outcome of nucleos(t)ide analog intervention in patients with preventive or on-demand therapy for hepatitis B virus reactivation.
    J Med Virol. 2020 Sep 17. doi: 10.1002/jmv.26526.
    PubMed     Abstract available


  62. HIGUCHI M, Tamaki N, Kurosaki M, Inada K, et al
    Changes of liver stiffness measured by magnetic resonance elastography during direct-acting antivirals treatment in patients with chronic Hepatitis C.
    J Med Virol. 2020 Sep 5. doi: 10.1002/jmv.26490.
    PubMed     Abstract available


    August 2020
  63. WOLF JM, Pereira VRZB, Simon D, Lunge VR, et al
    Evolutionary History of Hepatitis B Virus Genotype H.
    J Med Virol. 2020 Aug 27. doi: 10.1002/jmv.26463.
    PubMed     Abstract available


  64. KUMAR R, Chan KP, Ekstrom VSM, Wong JCC, et al
    Hepatitis C Virus antigen detection is an appropriate test for screening and early diagnosis of hepatitis C virus infection in at-risk populations and immunocompromised hosts.
    J Med Virol. 2020 Aug 14. doi: 10.1002/jmv.26433.
    PubMed     Abstract available


  65. REN F, Li W, Zhao S, Wang L, et al
    A3G-induced mutations show low prevalence and exhibit plus strand regional distribution in hepatitis B virus DNA from patients with non-hepatocellular carcinoma (HCC) and HCC.
    J Med Virol. 2020 Aug 11. doi: 10.1002/jmv.26418.
    PubMed     Abstract available


  66. AUZIN AM, Slavenburg S, Peters C, Boland G, et al
    Rapid, random-access, quantification of hepatitis B virus using the Cepheid Xpert(R) HBV Viral Load assay.
    J Med Virol. 2020 Aug 6. doi: 10.1002/jmv.26392.
    PubMed     Abstract available


  67. RIDRUEJO E, Pinero F, Mendizabal M, Cheinquer H, et al
    Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Real-world experience from HCV-LALREAN cohort.
    J Med Virol. 2020 Aug 4. doi: 10.1002/jmv.26383.
    PubMed     Abstract available


  68. UCHIDA Y, Nakao M, Tsuji S, Uemura H, et al
    Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
    J Med Virol. 2020;92:1370.
    PubMed    


    July 2020
  69. TRIPATHY AS, Sharma M, Thorat NC, Jadhav S, et al
    An outbreak of hepatitis E in Yavatmal, India, 2019.
    J Med Virol. 2020 Jul 31. doi: 10.1002/jmv.26377.
    PubMed     Abstract available


  70. PATACCINI G, Andrea Berini C, Rene Pedrozo W, Marcela Biglione M, et al
    First molecular epidemiological study of hepatitis B and D in individuals infected with human T- lymphotropic virus 1/2 from Argentina.
    J Med Virol. 2020 Jul 29. doi: 10.1002/jmv.26366.
    PubMed     Abstract available


  71. FAROOQ M, Rauf M, Tahir F, Manzoor S, et al
    "A comparative analysis of interferons and direct-acting antivirals on the expression of genes involved in hepatitis C pathogenesis".
    J Med Virol. 2020 Jul 24. doi: 10.1002/jmv.26351.
    PubMed     Abstract available


  72. RAMASWAMY M, Bruden D, Nolen LD, Mosites E, et al
    Hepatitis A vaccine immunogenicity 25 years after vaccination in Alaska.
    J Med Virol. 2020 Jul 22. doi: 10.1002/jmv.26327.
    PubMed     Abstract available


  73. LI MH, Chen QQ, Zhang L, Lu HH, et al
    Association of cytokines with hepatitis B virus and its antigen.
    J Med Virol. 2020 Jul 14. doi: 10.1002/jmv.26301.
    PubMed     Abstract available


  74. AL-SAFFAR OB, Ad'hiah AH
    Genetic variants in IL4RA, IL6, and IL12B genes and susceptibility to hepatitis B and C virus infections among Iraqi patients.
    J Med Virol. 2020 Jul 11. doi: 10.1002/jmv.26297.
    PubMed     Abstract available


  75. MODIYINJI AF, Rivero-Juarez A, Lopez-Lopez P, Atsama MA, et al
    First molecular characterization of the hepatitis E virus in humans in Cameroon: Confirmation of the HEV outbreak in Touboro, North-Cameroon.
    J Med Virol. 2020 Jul 8. doi: 10.1002/jmv.26277.
    PubMed     Abstract available


  76. MARTINEZ ALFREDO P, Pereson Matias J, Perez Paula S, Ines BM, et al
    Prevalence of Hepatitis E virus in children from Northeast of Argentina.
    J Med Virol. 2020 Jul 8. doi: 10.1002/jmv.26274.
    PubMed     Abstract available


  77. SATO N, Watanabe S, Miura K, Morimoto N, et al
    Clinical and virologic features of hepatitis E virus infection at a university hospital in Japan between 2000 and 2019.
    J Med Virol. 2020 Jul 1. doi: 10.1002/jmv.26248.
    PubMed     Abstract available


    June 2020
  78. DEBES JD, Groothuismink ZMA, de Man RA, Boonstra A, et al
    Association Between a Progesterone Receptor Mutation and Hepatitis E Sero-Positivity in Liver Transplant Recipients.
    J Med Virol. 2020 Jun 30. doi: 10.1002/jmv.26236.
    PubMed     Abstract available


  79. BANGUESES F, Abin-Carriquiry JA, Cancela F, Curbelo J, et al
    Serological and molecular prevalence of Hepatitis E Virus (HEV) among blood donors from Uruguay.
    J Med Virol. 2020 Jun 27. doi: 10.1002/jmv.26231.
    PubMed     Abstract available


  80. TIAN D, Yugo DM, Kenney SP, Lynn Heffron C, et al
    Dissecting the potential role of hepatitis E virus ORF1 non-structural gene in cross-species infection by using intergenotypic chimeric viruses.
    J Med Virol. 2020 Jun 26. doi: 10.1002/jmv.26226.
    PubMed     Abstract available


  81. KO K, Nagashima S, Yamamoto C, Takahashi K, et al
    18 Years Follow-up Cohort Study on Hepatitis B and C Virus Infections Related Long Term Prognosis among Hemodialysis Patients in Hiroshima.
    J Med Virol. 2020 Jun 24. doi: 10.1002/jmv.26215.
    PubMed     Abstract available


  82. HAN W, Li J, Zhou H, Qian J, et al
    Identification of the association of CD28(+) CD244(+) Tc17/IFN-gamma cells with chronic hepatitis C virus infection.
    J Med Virol. 2020 Jun 22. doi: 10.1002/jmv.26205.
    PubMed     Abstract available


  83. ABO EL-KHAIR SM, El-Alfy HA, Elsamanoudy AZ, Elhammady D, et al
    Development of a novel glycated protein-based fibrosis prediction score for determination of significant liver fibrosis in HCV-infected patients, a preliminary study.
    J Med Virol. 2020 Jun 19. doi: 10.1002/jmv.26204.
    PubMed     Abstract available


  84. LI Y, Li C, Wang J, Zhu C, et al
    A case series of COVID-19 patients with chronic hepatitis B virus infection.
    J Med Virol. 2020 Jun 19. doi: 10.1002/jmv.26201.
    PubMed     Abstract available


  85. XIAO L, Wu X, Zhang F, Wang J, et al
    Changes of inflammatory cytokines/chemokines during ravidasvir plus ritonavir-boosted danoprevir and ribavirin therapy for patients with genotype 1 b hepatitis C infection.
    J Med Virol. 2020 Jun 11. doi: 10.1002/jmv.26161.
    PubMed     Abstract available


  86. SEBASTIAO CS, Neto Z, Jandondo D, Mirandela M, et al
    HIV, hepatitis B virus, hepatitis C virus, and syphilis among pregnant women attending antenatal care in Luanda, Angola: seroprevalence and risk factors.
    J Med Virol. 2020 Jun 9. doi: 10.1002/jmv.26148.
    PubMed     Abstract available


    May 2020
  87. MOHAMADI M, Azarbayjani K, Mozhgani SH, Bamdad T, et al
    Hepatitis C virus alternative reading frame protein (ARFP): production, features and pathogenesis.
    J Med Virol. 2020 May 29. doi: 10.1002/jmv.26091.
    PubMed     Abstract available


  88. LIU Y, Zhao ZH, Lv XQ, Tang YW, et al
    Precise analysis of the effect of basal core promoter/precore mutations on the main phenotype of chronic hepatitis B in mouse models.
    J Med Virol. 2020 May 19. doi: 10.1002/jmv.26025.
    PubMed     Abstract available


  89. WAHID B, Shami K, Joiya SA, Ozuyar SEG, et al
    Comparing the risk of hypothyroidism in HCV patients treated with different DAA drugs combinations (sofosbuvir + interferon + ribavirin and sofosbuvir + daclatasvir + ribavirin).
    J Med Virol. 2020 May 17. doi: 10.1002/jmv.25931.
    PubMed     Abstract available


  90. ODJIDJA EN, Longo VL, Rizzatti G, Bandoh S, et al
    Coronavirus Disease 2019 and Viral Hepatitis coinfection: Provide guidelines for integrated screening and treatment.
    J Med Virol. 2020 May 15. doi: 10.1002/jmv.26021.
    PubMed     Abstract available


  91. WATANABE T, Tokumoto Y, Joko K, Michitaka K, et al
    Sex difference in the development of hepatocellular carcinoma after direct-acting antiviral therapy in patients with HCV infection.
    J Med Virol. 2020 May 6. doi: 10.1002/jmv.25984.
    PubMed     Abstract available


  92. AMSTUTZ A, Nsakala BL, Cheleboi M, Lejone TI, et al
    Low rates of active hepatitis B and C infections among adults and children living with HIV and taking antiretroviral therapy: a multicenter screening study in Lesotho.
    J Med Virol. 2020 May 5. doi: 10.1002/jmv.25970.
    PubMed     Abstract available


    April 2020
  93. KOC OM, Robaeys G, Topal H, Bielen R, et al
    Outcome in Caucasian patients with hepatitis B e antigen negative chronic infection: a long-term observational cohort study.
    J Med Virol. 2020 Apr 28. doi: 10.1002/jmv.25950.
    PubMed     Abstract available


  94. JAMIL Z, Waheed Y, Ahsan O, Najmi MH, et al
    Familial Clustering of Hepatitis C Virus in Pakistani Population.
    J Med Virol. 2020 Apr 22. doi: 10.1002/jmv.25926.
    PubMed     Abstract available


  95. KODANI M, Poe A, Drobeniuc J, Hayden T, et al
    Determination of potential biotin interference on accuracy of results of serologic assays for various viral hepatitis markers.
    J Med Virol. 2020 Apr 14. doi: 10.1002/jmv.25880.
    PubMed     Abstract available


  96. AVELLON A, Ala A, Diaz A, Domingo D, et al
    Clinical Performance of Determine(TM) HBsAg 2 rapid test for hepatitis B detection.
    J Med Virol. 2020 Apr 9. doi: 10.1002/jmv.25862.
    PubMed     Abstract available


    March 2020
  97. JAMSHIDI S, Bokharaei-Salim F, Esghaei M, Bastani MN, et al
    Occult HCV and Occult HBV Co-infection in Iranian Human Immunodeficiency Virus-Infected Individuals.
    J Med Virol. 2020 Mar 31. doi: 10.1002/jmv.25808.
    PubMed     Abstract available


    January 2020
  98. YANG J, Xiong Y, Zhou L, Huang Y, et al
    Soluble E-cadherin is associated with oxidative stress in patients with chronic HBV infection.
    J Med Virol. 2020;92:34-44.
    PubMed     Abstract available


    July 2019
  99. FENG S, Wang Z, Zhao Y, Ji G, et al
    Long non-coding RNA GAS5 does not regulate HBV replication.
    J Med Virol. 2019 Jul 13. doi: 10.1002/jmv.25547.
    PubMed     Abstract available


    April 2019
  100. EL KASSAS M, Alboraie M, Omar H, El Latif YA, et al
    High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naive and experienced chronic hepatitis C genotype 4: Real world results.
    J Med Virol. 2019 Apr 5. doi: 10.1002/jmv.25478.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: